Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Indivior plc
High court is to determine whether the government can dismiss an FCA complaint after initially declining to take it on. In recent years, the government has dismissed numerous qui tam suits against pharma companies in which it did not intervene.
Former chief medical officer’s conviction for misbranding Suboxone does not warrant mandatory exclusion from healthcare programs, complaint argues. It says individuals in similar situations, specifically former Purdue execs, were subject to permissive exclusion.
The UK firm has out-licensed its NRF2 activator programme to AstraZeneca in its third major deal of the year as it works to stabilize cash flow through a broad-ranging approach to partnerships.
Some observers believe Indivior is paying a very reasonable price to get hold of OPNT003, an intranasal formulation of the opioid antagonist nalmefene, which is expected to be filed with the US FDA by the end of the year.
- Drug Delivery
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Indivior Inc.
- Indivior UK Limited
- Reckitt Benckiser Pharmaceuticals Inc. (RBP)